The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Abstract Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who have rec...

Full description

Saved in:
Bibliographic Details
Main Authors: Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial
Format: Article
Language:English
Published: Nature Publishing Group 2025-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-025-01212-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items